Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 658 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 658 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total value of $65,800.00. Following the transaction, the senior vice president owned 616 shares in the company, valued at $61,600. This trade represents a 51.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Tuesday, August 18th, Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $100.00, for a total transaction of $4,000,000.00.
• On Monday, August 3rd, Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $105.29, for a total transaction of $193,733.60.
• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total transaction of $264,458.30.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $100.63 on Friday. The firm’s fifty day simple moving average is $109.55 and its two-hundred day simple moving average is $101.74. Mirum Pharmaceuticals, Inc. has a 52-week low of $63.23 and a 52-week high of $130.00. The company has a market cap of $6.53 billion, a price-to-earnings ratio of -6.92 and a beta of 0.49. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The company had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The firm’s revenue for the quarter was up 37.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) EPS. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Comerica Bank boosted its holdings in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Mirum Pharmaceuticals by 307.3% in the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after purchasing an additional 37,028 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Mirum Pharmaceuticals by 7.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after purchasing an additional 1,720 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of Mirum Pharmaceuticals in the first quarter valued at approximately $217,000. Finally, Empowered Funds LLC lifted its position in Mirum Pharmaceuticals by 15.4% during the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after buying an additional 5,120 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on MIRM shares. UBS Group set a $137.00 target price on Mirum Pharmaceuticals in a research report on Thursday, August 27th. Stifel Nicolaus set a $136.00 price target on Mirum Pharmaceuticals in a research report on Thursday, May 7th. Citigroup reissued a “market outperform” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, August 27th. Citizens Jmp reissued a “market outperform” rating and issued a $137.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, August 27th. Finally, Weiss Ratings upgraded Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.31.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.